China has put Illumina on its ‘unreliable entity list’ after the US imposed sanctions on Beijing Genomics Institute, also a ...

After the National Institutes of Health (NIH) announced late Friday that it would be following a Trump administration ...

A stand-alone sequencing approach was accurate, cost effective and efficient for analyzing resistant pathogens and ...

The general mood among these heavyweight investors is divided, with 37% leaning bullish and 37% bearish. Among these notable options, 4 are puts, totaling $366,099, and 4 are calls, amounting to ...

Fintel reports that on February 10, 2025, Barclays downgraded their outlook for Illumina (NasdaqGS:ILMN) from Equal-Weight to ...

Element Biosciences’ bid to claim a slice of a DNA sequencing technology market dominated by Illumina has been helped by an impressive $277 million financing round backed by a wide range of ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...

The placement of Illumina in China's unreliable entity list could have disruptive implications. Read why I remain bullish on ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Precision medicine is an innovative approach in healthcare that takes into account individual differences in genes, ...

Genomics is bringing in a new wave of money from an unlikely group of investors — health systems. More providers are ...